SEC Tracker
Get the app

Inmune Bio INMB

Inmune Bio Q2 FY24: revenue $0; diluted EPS −$0.50

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Inmune Bio reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
  2. Net income−$9.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.50No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$31.1MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$7.9MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Inmune Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Metagenomi Therapeutics MGX public float $51M, Jun 30, 2025
  2. Invivyd IVVD public float $51M, Jun 30, 2025
  3. Greenland Mines GRML public float $53M, Jun 30, 2025
  4. Senti Biosciences Holdings SNTI public float $53M, Jun 30, 2025
  5. Precision Biosciences DTIL public float $47M, Jun 30, 2025